B-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma

British Journal of Cancer

Volumn 108, Issue 12, 2013, Pages 2485-2494

  Pasquier, E ^a,b   Street, J ^a   Pouchy, C ^a,h   Carre, M ^c   Gifford, A J ^a,d   Murray, J ^a   Norris, M D ^a   Trahair, T ^a,e   Andre, N ^b,c,f   Kavallaris, M ^a,g  

^a University of New South Wales   (Australia)

^b Metronomics Global Health Initiative   (France)

^c University of the Mediterranean Aix Marseille II   (France)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e SYDNEY CHILDREN'S HOSPITAL   (Australia)

^f TIMONE HOSPITAL   (France)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BUTOXAMINE; CARVEDILOL; DOXORUBICIN; LABETALOL; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NEBIVOLOL; PROPRANOLOL; VINCRISTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; ABDOMINAL TUMOR; ANIMAL; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TRANSGENIC MOUSE; VASCULARIZATION;

ABDOMINAL NEOPLASMS; ADRENERGIC BETA-ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA;

EID: 84879685044     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.205     Document Type: Article

References (48)

1. Bachmakov I, Werner U, Endress B, Auge D, Fromm MF (2006) Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol 20: 273-282.
2. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 29: 2635-2644.
3. Cheng AJ, Cheng NC, Ford J, Smith J, Murray JE, Flemming C, Latowska M, Jackson MS, Hackett CS, Weiss WA, Marshall GM, Kees UR, Norris MD, Haber M (2007) Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. Eur J Cancer 43: 1467-1475.
4. Chim H, Armijo BS, Miller E, Gliniak C, Serret MA, Gosain AK (2012) Propranolol induces regression of hemangioma cells through HIF-1alpha-mediated inhibition of VEGF-A. Ann Surg 256: 146-156.
5. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
6. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
7. Cole SW, Sood AK (2011) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18: 1201-1206.
8. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK. INRG Task Force (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27: 289-297.
9. De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N, Geppetti P (2011) Treatment with beta-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 171: 779-781.
10. Diaz ES, Karlan BY, Li AJ (2012) Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 127: 375-378.
11. Erguven M, Yazihan N, Aktas E, Sabanci A, Li CJ, Oktem G, Bilir A (2010) Carvedilol in glioma treatment alone and with imatinib in vitro. Int J Oncol 36: 857-866.
12. Haber M, Norris MD, Kavallaris M, Bell DR, Davey RA, White L, Stewart BW (1989) Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein. Cancer Res 49: 5281-5287.
13. Hamilton KO, Yazdanian MA, Audus KL (2001) Modulation of P-glycoprotein activity in Calu-3 cells using steroids and beta-ligands. Int J Pharm 228: 171-179.
14. Hermans DJ, van Beynum IM, van der Vijver RJ, Kool LJ, de Blaauw I, van der Vleuten CJ (2011) Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. J Pediatr Hematol Oncol 33: e171-e173.
15. Hernandez MR, Shamberger RC, Seefelder C (2009) Catecholamine-secreting neuroblastoma in a 4-month-old infant: perioperative management. J Clin Anesth 21: 54-56.
16. Ishola TA, Chung DH (2007) Neuroblastoma. Surg Oncol 16: 149-156.
17. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K (1999) Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol 58: 1801-1806.
18. Kakumoto M, Sakaeda T, Takara K, Nakamura T, Kita T, Yagami T, Kobayashi H, Okamura N, Okumura K (2003) Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Cancer Sci 94: 81-86.
19. Kwon Y, Kamath AV, Morris ME (1996) Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles. J Pharm Sci 85: 935-939.
20. Lamkin DM, Sloan EK, Patel AJ, Chiang BS, Pimentel MA, Ma JC, Arevalo JM, Morizono K, Cole SW (2012) Chronic stress enhances progression of acute lymphoblastic leukemia via beta-adrenergic signaling. Brain Behav Immun 26: 635-641.
21. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A (2008) Propranolol for severe hemangiomas of infancy. N Engl J Med 358: 2649-2651.
22. Lemeshow S, Sorensen HT, Phillips G, Yang EV, Antonsen S, Riis AH, Lesinski GB, Jackson R, Glaser R (2011) Beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 20: 2273-2279.
23. Liao X, Che X, Zhao W, Zhang D, Long H, Chaudhary P, Li H (2010) Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro. Radiat Oncol 5: 98.
24. MacKenzie KL, Franco S, Naiyer AJ, May C, Sadelain M, Rafii S, Moore MA (2002) Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene 21: 4200-4211.
25. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 27: 1007-1013.
26. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29: 2645-2652.
27. Moore HC, Wood KM, Jackson MS, Lastowska MA, Hall D, Imrie H, Redfern CP, Lovat PE, Ponthan F, O'Toole K, Lunec J, Tweddle DA (2008) Histological profile of tumours from MYCN transgenic mice. J Clin Pathol 61: 1098-1103.
28. Norris MD, Burkhart CA, Marshall GM, Weiss WA, Haber M (2000) Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med Pediatr Oncol 35: 585-589.
29. Oakes SA, Korsmeyer SJ (2004) Untangling the web: mitochondrial fission and apoptosis. Dev Cell 7: 460-462.
30. Pappas L, Shamberger RC, Seefelder C (2010) Giant, dopamine secreting thoracoabdominal neuroblastoma in a 2-year-old: rapid preoperative blockade with labetalol. J Pediatr Hematol Oncol 32: 163-166.
31. Pasquier E, Carre M, Pourroy B, Camoin L, Rebai O, Briand C, Braguer D (2004) Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 3: 1301-1310.
32. Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C, Kavallaris M, Andre N (2011) Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2: 797-809.
33. Pasquier E, Sinnappan S, Munoz MA, Kavallaris M (2010) ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther 9: 1408-1418.
34. Pasquier E, Tuset MP, Street J, Sinnappan S, Mackenzie KL, Braguer D, Andre N, Kavallaris M (2013) Concentration-and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis 16: 373-386.
35. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1: 628-638.
36. Reis Y, Bernardo-Faura M, Richter D, Wolf T, Brors B, Hamacher-Brady A, Eils R, Brady NR (2012) Multi-parametric analysis and modeling of relationships between mitochondrial morphology and apoptosis. PLoS One 7: e28694.
37. Rovini A, Savry A, Braguer D, Carre M (2011) Microtubule-targeted agents: when mitochondria become essential to chemotherapy. Biochim Biophys Acta 1807: 679-688.
38. Savry A, Carre M, Berges R, Rovini A, Pobel I, Chacon C, Braguer D, Bourgarel-Rey V (2013) Bcl2 enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: consequences in lung cancer treatment. Neoplasia 15: 49-60.
39. Shan T, Ma Q, Zhang D, Guo K, Liu H, Wang F, Wu E (2011) Beta2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur J Pharmacol 665: 1-7.
40. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM (2010) Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 28: 4969-4975.
41. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SW (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70: 7042-7052.
42. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12: 939-944.
43. Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR (2013) Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24: 1312-1319.
44. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985-2995.
45. Wigler PW, Patterson FK (1994) Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochim Biophys Acta 1189: 1-6.
46. Winer J, Jung CK, Shackel I, Williams PM (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270: 41-49.
47. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham D, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA. An ad hoc committee of the National Cancer Research Institute (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
48. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363: 1324-1334.